Compare CSWC & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSWC | MDWD |
|---|---|---|
| Founded | 1961 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Textiles | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 230.7M |
| IPO Year | N/A | 2014 |
| Metric | CSWC | MDWD |
|---|---|---|
| Price | $22.19 | $18.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $23.50 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 578.5K | 95.0K |
| Earning Date | 11-03-2025 | 11-20-2025 |
| Dividend Yield | ★ 11.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.62 | N/A |
| Revenue | ★ $217,271,000.00 | $20,932,000.00 |
| Revenue This Year | $13.78 | $15.89 |
| Revenue Next Year | $7.08 | $25.33 |
| P/E Ratio | $13.73 | ★ N/A |
| Revenue Growth | ★ 11.39 | 6.15 |
| 52 Week Low | $17.46 | $14.14 |
| 52 Week High | $23.86 | $22.51 |
| Indicator | CSWC | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 67.09 | 59.99 |
| Support Level | $21.22 | $18.71 |
| Resistance Level | $22.52 | $19.63 |
| Average True Range (ATR) | 0.31 | 0.71 |
| MACD | 0.10 | 0.18 |
| Stochastic Oscillator | 83.10 | 79.22 |
Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.